Document is current
Any future updates will be listed below
-
Authors
Irving, Melita http://orcid.org/0000-0002-2997-4461
AlSayed, Moeenaldeen
Arundel, Paul
Baujat, Geneviève
Ben-Omran, Tawfeg
Boero, Silvio
Cormier-Daire, Valérie
Fredwall, Svein
Guillen-Navarro, Encarna
Hoyer-Kuhn, Heike
Kunkel, Philip
Lampe, Christian
Maghnie, Mohamad
Mohnike, Klaus
Mortier, Geert
Sousa, Sérgio B.
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical (BioMarin Pharmaceutical)
Sanofi (Sanofi)
Ascendis Pharma (Ascendis Pharma)
QED Therapeutics (QED Therapeutics)
Pfizer (Pfizer)
- License Information
-
More Information
Article History
Received: 2 March 2023
Accepted: 5 July 2023
First Online: 27 July 2023
Declarations
: <b>Ethics approval and consent to participate</b>.
: Not applicable.
: <b>Consent for publication</b>.
: Not applicable.
: MAS, VCD, SF, HHK, CL, PK, TBO have no conflict of interest to declare. PA has received honoraria or consultation fees from BioMarin and support as a local principal investigator in achondroplasia clinical trials from BioMarin, Pfizer and QED. GB has received honoraria or consultation fees from BioMarin and funding from Ascendis for clinical trials. SB received honoraria or consultation fees from BioMarin. EGN has received honoraria or consultation fees from BioMarin. MI has received honoraria or consultation fees from Alexion, Ascendis Pharma, BioMarin, Innoskel, Ipsen, Kyowa Kirin, Novo Nordisk, QED Therapeutics, Sanofi and Theracon/Pfizer. MM has received grants/research support from Pfizer, Novo Nordisk and Merck, and honoraria or consultation fees from Pfizer, Novo Nordisk, Sandoz and BioMarin. KM has received grants/research support from BioMarin and honoraria or consultation fees from BioMarin and QED. GM has received honoraria or consultation fees from BioMarin, Ipsen and Pfizer. SS received honoraria or consultation fees from BioMarin Ascendis, Kyowa Kirin.
